Barclays Maintains Overweight on Tarsus Pharmaceuticals, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $50 to $60.
May 10, 2024 | 7:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has maintained its Overweight rating on Tarsus Pharmaceuticals and increased the price target from $50 to $60, indicating a positive outlook on the company's future performance.
The upgrade in the price target by a reputable analyst like Barclays suggests a strong confidence in Tarsus Pharmaceuticals' future growth and performance. This is likely to be viewed positively by the market, potentially leading to an increase in the stock price in the short term as investors adjust their expectations based on this new analyst outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100